KALOCYTE
Kalocyte is a pre-clinical stage healthcare biotech startup company that provides artificial red blood cell substitutes used for trauma care related services. The company develops a demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable, or in short supply. Kalocyte was founded in 2016 and is headquartered in Baltimore, Maryland.
KALOCYTE
Social Links:
Industry:
Biotechnology Emergency Medicine Health Care
Founded:
2016-01-01
Address:
Baltimore, Maryland, United States
Country:
United States
Website Url:
http://www.kalocyte.com
Total Employee:
1+
Status:
Active
Total Funding:
1.47 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager WordPress Apache
Similar Organizations
Aulos Bioscience
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics.
Current Employees Featured
Founder
Investors List
New York Blood Center
New York Blood Center investment in Seed Round - Kalocyte
(Momentum Fund) University System of Maryland
(Momentum Fund) University System of Maryland investment in Seed Round - Kalocyte
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Kalocyte
BioGenerator
BioGenerator investment in Seed Round - Kalocyte
St. Louis Arch Angels
St. Louis Arch Angels investment in Seed Round - Kalocyte
Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship
Skandalaris Center for Interdisciplinary Innovation and Entrepreneurship investment in Grant - Kalocyte
Official Site Inspections
http://www.kalocyte.com
- Host name: box2046.bluehost.com
- IP address: 67.222.38.82
- Location: Provo United States
- Latitude: 40.2342
- Longitude: -111.6442
- Metro Code: 770
- Timezone: America/Denver
- Postal: 84606
More informations about "Kalocyte"
ABOUT KALOCYTE
KaloCyte was incorporated in 2016 by co-founders Dr. Doctor, Dipanjan Pan, PhD and Phil Spinella, MD – expert researchers in physiology, bioengineering, and trauma care. KaloCyte …See details»
Kalocyte - Crunchbase Company Profile & Funding
Kalocyte is a pre-clinical stage healthcare biotech startup company that provides artificial red blood cell substitutes used for trauma care related services. The company develops a …See details»
OUR TEAM - KaloCyte
KaloCyte Company Profile 2024: Valuation, Funding
KaloCyte General Information Description. Developer of red blood cell substitutes designed for trauma care-related services. The company's cell substitutes are designed for context-dependent oxygen delivery, while minimizing …See details»
KaloCyte, Inc. - LinkedIn
KaloCyte, Inc. Biotechnology Research Baltimore, Maryland 1,917 followers Developing ErythroMer, bio-inspired artificial RBC substitute for use when stored blood is not available.See details»
KaloCyte - Products, Competitors, Financials, Employees, …
KaloCyte's products are primarily targeted towards the healthcare industry, specifically in areas of trauma care and transfusion medicine. It was founded in 2016 and is based in Baltimore, …See details»
KaloCyte Company Profile - Office Locations, Competitors ... - Craft
KaloCyte has 5 employees at their 1 location and $800 k in total funding,. See insights on KaloCyte including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Kalocyte | Seed - National Institutes of Health
A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock A locked padlock) or https ... KaloCyte was founded by a …See details»
Kalocyte - Funding, Financials, Valuation & Investors - Crunchbase
Kalocyte provides red blood cell substitutes used for trauma care related services. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... How …See details»
C-Suite Insights with Elaine Haynes, CEO of KaloCyte
Feb 12, 2024 Please tell us a little bit about yourself and your organization. I am CEO of KaloCyte, Inc., a pre-clinical biotech startup developing an artificial red blood cell substitute …See details»
KaloCyte Closes Investment from New York Blood Center
Jul 20, 2022 KaloCyte’s mission is to make an easy-to-use, shelf-stable red blood substitute available anywhere and at any time. ... (NYBC) is a nonprofit organization that is one of the …See details»
From Pharma to Biotech: Meet Elaine Haynes CEO of Artificial
Sep 27, 2023 When KaloCyte was first formed, the company was based in St. Louis. Under her guidance, KaloCyte relocated to Baltimor e to be closer to investors. Haynes describes her …See details»
Kalocyte - Contacts, Employees, Board Members, Advisors & Alumni
Kalocyte has 4 current employee profiles, including Chief Scientific Officer and Founding Partner Allan Doctor. Allan Doctor Chief Scientific Officer and Founding Partner Phil Spinella Co-FounderSee details»
KaloCyte | Maryland Momentum Fund
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to …See details»
KaloCyte Relocates to Downtown Baltimore as Co-Founders Join
Sep 23, 2019 KaloCyte’s relocation from St. Louis brings it closer to major stakeholders and funders, including the National Institutes of Health (NIH) National Heart, Lung, and Blood …See details»
KaloCyte Closes Investment from New York Blood Center
Jul 20, 2022 BALTIMORE--(BUSINESS WIRE)-- KaloCyte, Inc., a developer of bio-inspired red blood cell substitute ErythroMer™, today announced it has closed an investment from New …See details»
NEWS - KaloCyte
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to …See details»
BioGenerator Company KaloCyte Partners on $46M DARPA …
By Alex Keown February 6, 2023. KaloCyte’s experimental synthetic red blood cell product ErythroMer could provide a solution to the high need for treating trauma in both military and …See details»
Baltimore’s KaloCyte Partners on $46M DARPA Program to …
Feb 6, 2023 “This partnership with DARPA is highly complementary to our work,” Elaine Haynes, President and Chief Executive Officer of KaloCyte said. DARPA will provide $46 million in …See details»